<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772212</url>
  </required_header>
  <id_info>
    <org_study_id>116827</org_study_id>
    <nct_id>NCT01772212</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Terbinafine 250 mg</brief_title>
  <official_title>Bioequivalence Study Between Two Medications for the Oral Administration of Terbinafine 250 mg in Oral Solids in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to confirm if two formulations of terbinafine (tablets) are
      bioequivalent.

      Test product was Xilatril® 250 mg (Laboratorios Dermatológicos Darier) and reference product
      Lamisil® 250 mg (Novartis). One tablet was the single dosage.

      The study was prospective, open-label, randomized, crossover, single dose, with 02
      treatments, 02 sequences and 02 periods, under fasting conditions.

      The population was composed of 30 healthy volunteers, both genders, adults between 18-50
      years.

      The comparative bioavailability of the two formulations was evaluated based in statistical
      comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations
      in blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2011</start_date>
  <completion_date type="Actual">March 15, 2011</completion_date>
  <primary_completion_date type="Actual">March 15, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of drug terbinafine</measure>
    <time_frame>0.0, 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, and 24.0 hours post dose</time_frame>
    <description>pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of drug terbinafine</measure>
    <time_frame>0.0, 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 3.5, 4.0, 6.0, 8.0, 10.0, 12.0, and 24.0 hours post dose</time_frame>
    <description>pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>A(test)/B(reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial administration of test and crossover to reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(reference)/A(test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial administration of reference and crossover to test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine 250 mg</intervention_name>
    <description>Test product</description>
    <arm_group_label>A(test)/B(reference)</arm_group_label>
    <arm_group_label>B(reference)/A(test)</arm_group_label>
    <other_name>Xilatril® is a registered trademark of Laboratorios Dermatológicos Darier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine 250 mg</intervention_name>
    <description>Reference product</description>
    <arm_group_label>A(test)/B(reference)</arm_group_label>
    <arm_group_label>B(reference)/A(test)</arm_group_label>
    <other_name>Lamisil® is a registered trademark of Novartis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria: Males 18-50 years. Healthy based on comprehensive medical history, lab
        tests, Chest x-ray, Electrocardiogram, negative tests for Hepatitis B and C, and HIV.
        Negative urine doping test. BMI 19-26.5 kg/m2. Lab test in normal range +/- 10%. Blood
        pressure 139-90/89-50, heart rate 100-55, respiratory rate 24-17, temperature 37.5-35 °C.
        Non-smoking at least for 10 hrs before study. Written informed consent. -

        Exclusion Criteria:

        Hypersensitivity to study medication or other related drug. History of cardiovascular,
        renal, hepatic, metabolic, gastrointestinal, neurologic, endocrine, hematopoietic,
        psychiatric or organic condition.

        Requiring any drug interfering with minocycline pharmacokinetics. Exposed to inducers or
        inhibitors of hepatic enzymes. Intake of possible toxic drugs 30 days before study. Intake
        of any drug 14 days or 7 half-lives before study. Hospitalization or severe disease 60 days
        before study. Receiving investigational drug out of study center 30 days before study.
        Blood loss or blood donation =&gt;450 ml 60 days before study. Recent history of drug abuse
        including alcohol. Intake of xanthine containing products 10 hrs before study. Intake of
        grapefruit juice or hot-spice 10 hrs before study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/116827?search=study&amp;search_terms=116827#rs</url>
    <description>Results for study 116827 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mexico</keyword>
  <keyword>terbinafine</keyword>
  <keyword>mycoses</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

